Cargando…
Vaxman I, Gertz MA. How I approach smoldering multiple myeloma. Blood. 2022;140(8):828-838.
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163309/ https://www.ncbi.nlm.nih.gov/pubmed/36929433 http://dx.doi.org/10.1182/blood.2022019523 |
Ejemplares similares
-
Steffin DHM, Muhsen IN, Hill LC, et al. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022;140(1):16-24.
Publicado: (2023) -
Pagano L, Salmanton-García J, Marchesi F, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood. 2022;140(26):2773-2787.
Publicado: (2023) -
Jutzi JS, Marneth AE, Ciboddo M, et al. Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs. Blood. 2022;140(11):1291-1304.
Publicado: (2023) -
Wang D, Sun Z, Zhu X, et al. GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post–allo-HSCT. Blood. 2022;140(26):2788-2804.
Publicado: (2023) -
How I approach smoldering multiple myeloma
por: Vaxman, Iuliana, et al.
Publicado: (2022)